

1-1 By: Dominguez, et al. H.B. No. 1802
 1-2 (Senate Sponsor - Campbell, et al.)
 1-3 (In the Senate - Received from the House May 10, 2021;
 1-4 May 17, 2021, read first time and referred to Committee on Veteran
 1-5 Affairs & Border Security; May 19, 2021, reported favorably by the
 1-6 following vote: Yeas 6, Nays 0; May 19, 2021, sent to printer.)

1-7 COMMITTEE VOTE

	Yea	Nay	Absent	PNV
1-8				
1-9	X			
1-10	X			
1-11	X			
1-12	X			
1-13	X			
1-14			X	
1-15	X			

1-16 A BILL TO BE ENTITLED
 1-17 AN ACT

1-18 relating to a study on the use of alternative therapies for treating
 1-19 post-traumatic stress disorder.

1-20 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-21 SECTION 1. (a) In this Act, "commission" means the Health
 1-22 and Human Services Commission.

1-23 (b) The commission, in collaboration with Baylor College of
 1-24 Medicine and in partnership with a military veterans hospital or a
 1-25 medical center that provides medical care to veterans, shall
 1-26 conduct a study on the efficacy of using alternative therapies,
 1-27 including the use of 3,4-methylenedioxymethamphetamine (MDMA),
 1-28 psilocybin, and ketamine, in the treatment of veterans who suffer
 1-29 from post-traumatic stress disorder.

1-30 (c) In conducting the study described by Subsection (b) of
 1-31 this section, the commission in collaboration with the Baylor
 1-32 College of Medicine shall:

1-33 (1) perform a clinical trial on the therapeutic
 1-34 efficacy of using psilocybin in the treatment of
 1-35 treatment-resistant post-traumatic stress disorder in veterans;
 1-36 and

1-37 (2) review current literature regarding:

1-38 (A) the safety and efficacy of
 1-39 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
 1-40 ketamine in the treatment of post-traumatic stress disorder; and

1-41 (B) the access veterans have to
 1-42 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
 1-43 ketamine for treatment of post-traumatic stress disorder in the
 1-44 United States.

1-45 (d) The commission shall prepare and submit to the governor,
 1-46 the lieutenant governor, the speaker of the house of
 1-47 representatives, and each member of the legislature:

1-48 (1) quarterly reports on the progress of the study
 1-49 conducted under this section; and

1-50 (2) not later than December 1, 2024, a written report
 1-51 containing the results of the study conducted under this section
 1-52 and any recommendations for legislative or other action.

1-53 (e) The commission shall ensure any protected health
 1-54 information collected during a clinical trial conducted under
 1-55 Subsection (c) of this section and reported under Subsection (d) of
 1-56 this section does not personally identify an individual.

1-57 (f) This Act expires September 1, 2025.

1-58 SECTION 2. This Act takes effect immediately if it receives
 1-59 a vote of two-thirds of all the members elected to each house, as
 1-60 provided by Section 39, Article III, Texas Constitution. If this
 1-61 Act does not receive the vote necessary for immediate effect, this

2-1 Act takes effect September 1, 2021.

2-2 * * * * *